Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High G rade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Biological: Rituximab; &n...
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone
Conditions:   Clinical Response;   Histopathological Response;   Prognosis Intervention:   Drug: first-line chemotherapy Sponsors:   Peking University People's Hospital;   Peking University Shougang Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Sleep Apnea and Lung Cancer
Condition:   Locally Advanced Non Small Cell Lung Cancer Intervention:   Diagnostic Test: sleep study and blood sample Sponsor:   Zagazig University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Radiosurgery Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
Conditions:   Prostate Cancer;   Castration-resistant Prostate Cancer Interventions:   Drug: SHR3680;   Drug: SHR2554 Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

TS Overexpression in SCLC: Mechanism and Therapeutic Targeting
Condition:   Small Cell Lung Cancer Intervention:   Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
Condition:   Lung Neoplasm Intervention:   Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI);   Lung Cancer Initiative of North Carolina Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.
Condition:   Triple Negative Breast Neoplasms Interventions:   Drug: Durvalumab;   Drug: Selumetinib;   Drug: Capivasertib;   Drug: Danvatirsen;   Drug: Oleclumab;   Drug: Paclitaxel Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Hollings Cancer Center Varenicline Sampling Study
Conditions:   Smoking;   Smoking Cessation;   Smoking, Tobacco;   Smoking, Cigarette Intervention:   Drug: Varenicline 0.5 MG Sponsor:   Medical University of South Carolina Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Conditions:   Breast Cancer Metastatic;   Breast Cancer Interventions:   Drug: Olaparib;   Drug: Vorinostat Sponsors:   Jenny C. Chang, MD;   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Condition:   Triple Negative Breast Cancer (TNBC) Interventions:   Biological: spartalizumab;   Biological: LAG525;   Drug: NIR178;   Drug: capmatinib;   Biological: MCS110;   Biological: canakinumab Sponsor:   Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Genomic Analysis of Evolution of Epithelia Ovarian Tumors
Conditions:   Epithelial Ovarian Cancer;   Epithelial Ovarian Tumor of Borderline Malignancy;   Driving Mutations;   Progression-free Survival Intervention:   Sponsor:   Lei Li Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis
Condition:   Hepatocellular Carcinoma Interventions:   Diagnostic Test: contrast-enhanced ultrasound;   Diagnostic Test: EOB-MRI Sponsors:   Seoul National University Hospital;   Bracco Corporate Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients
Condition:   Colorectal Cancer Interventions:   Drug: Probiotic Formula Capsule;   Drug: Placebos Sponsors:   University of Jordan;   King Hussein Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Conditions:   Stage III Non-small-cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Radiotherapy Side Effect Intervention:   Radiation: Heterogeneously Hypofractionated Radiotherapy Sponsors:   Danish Lung Cancer Group;   Odense University Hospital;   Rigshospitalet, Denmark;   Vejle Hospital;   Herlev Hospital;   Aarhus University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Efficacy Study of CPC634 (CriPec ® Docetaxel) in Platinum Resistant Ovarian Cancer
Conditions:   Cancer;   Ovarian Cancer Intervention:   Drug: CPC634 (CriPec® docetaxel) Sponsor:   Cristal Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Study Assessing the Safety and Performance of Smart Matrix ®
Conditions:   Basal Cell Carcinoma;   Squamous Cell Carcinoma Intervention:   Device: Smart Matrix scaffold Sponsor:   Smart Matrix Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Multi-omics Study of Epithelial Ovarian Cancer
Conditions:   Epithelial Ovarian Cancer;   Tumor Invasiveness;   Whole Exome Sequencing;   Transcriptomics;   Metabolomics;   Tumorigenesis Intervention:   Combination Product: A multi-omics analysis Sponsor:   Lei Li Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002)
Condition:   Advanced Solid Neoplasms Intervention:   Drug: Olaparib Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients
Condition:   Breast Neoplasms Intervention:   Drug: Cefazolin/clindamycin Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Condition:   Breast Cancer Interventions:   Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2;   Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2;   Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg;   Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor:   New York University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition:   Treatment of Malignancy Associated Weight Loss or Anorexia in Patients With NSCLC Interventions:   Drug: Anamorelin Hydrochloride;   Drug: Placebo Oral Tablet Sponsor:   Helsinn Healthcare SA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition:   Treatment of Malignancy Associated Weight Loss or Anorexia in Patients With NSCLC Interventions:   Drug: anamorelin HCl;   Drug: Placebo Oral Tablet Sponsor:   Helsinn Healthcare SA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer (ALTER-L029)
Condition:   Non-Small Cell Lung Cancer Stage III Intervention:   Drug: Anlotinib Sponsor:   Anhui Shi, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High G rade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Biological: Rituximab; &n...
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Multi-omics Study of Epithelial Ovarian Cancer
Conditions:   Epithelial Ovarian Cancer;   Tumor Invasiveness;   Whole Exome Sequencing;   Transcriptomics;   Metabolomics;   Tumorigenesis Intervention:   Combination Product: A multi-omics analysis Sponsor:   Lei Li Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002)
Condition:   Advanced Solid Neoplasms Intervention:   Drug: Olaparib Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients
Condition:   Breast Neoplasms Intervention:   Drug: Cefazolin/clindamycin Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Condition:   Breast Cancer Interventions:   Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2;   Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2;   Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg;   Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor:   New York University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone
Conditions:   Clinical Response;   Histopathological Response;   Prognosis Intervention:   Drug: first-line chemotherapy Sponsors:   Peking University People's Hospital;   Peking University Shougang Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition:   Treatment of Malignancy Associated Weight Loss or Anorexia in Patients With NSCLC Interventions:   Drug: Anamorelin Hydrochloride;   Drug: Placebo Oral Tablet Sponsor:   Helsinn Healthcare SA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition:   Treatment of Malignancy Associated Weight Loss or Anorexia in Patients With NSCLC Interventions:   Drug: anamorelin HCl;   Drug: Placebo Oral Tablet Sponsor:   Helsinn Healthcare SA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer (ALTER-L029)
Condition:   Non-Small Cell Lung Cancer Stage III Intervention:   Drug: Anlotinib Sponsor:   Anhui Shi, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis
Condition:   Hepatocellular Carcinoma Interventions:   Diagnostic Test: contrast-enhanced ultrasound;   Diagnostic Test: EOB-MRI Sponsors:   Seoul National University Hospital;   Bracco Corporate Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Study Assessing the Safety and Performance of Smart Matrix ®
Conditions:   Basal Cell Carcinoma;   Squamous Cell Carcinoma Intervention:   Device: Smart Matrix scaffold Sponsor:   Smart Matrix Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Sleep Apnea and Lung Cancer
Condition:   Locally Advanced Non Small Cell Lung Cancer Intervention:   Diagnostic Test: sleep study and blood sample Sponsor:   Zagazig University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Radiosurgery Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
Conditions:   Prostate Cancer;   Castration-resistant Prostate Cancer Interventions:   Drug: SHR3680;   Drug: SHR2554 Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

TS Overexpression in SCLC: Mechanism and Therapeutic Targeting
Condition:   Small Cell Lung Cancer Intervention:   Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
Condition:   Lung Neoplasm Intervention:   Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI);   Lung Cancer Initiative of North Carolina Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.
Condition:   Triple Negative Breast Neoplasms Interventions:   Drug: Durvalumab;   Drug: Selumetinib;   Drug: Capivasertib;   Drug: Danvatirsen;   Drug: Oleclumab;   Drug: Paclitaxel Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Hollings Cancer Center Varenicline Sampling Study
Conditions:   Smoking;   Smoking Cessation;   Smoking, Tobacco;   Smoking, Cigarette Intervention:   Drug: Varenicline 0.5 MG Sponsor:   Medical University of South Carolina Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Conditions:   Breast Cancer Metastatic;   Breast Cancer Interventions:   Drug: Olaparib;   Drug: Vorinostat Sponsors:   Jenny C. Chang, MD;   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Condition:   Triple Negative Breast Cancer (TNBC) Interventions:   Biological: spartalizumab;   Biological: LAG525;   Drug: NIR178;   Drug: capmatinib;   Biological: MCS110;   Biological: canakinumab Sponsor:   Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

A Genomic Analysis of Evolution of Epithelia Ovarian Tumors
Conditions:   Epithelial Ovarian Cancer;   Epithelial Ovarian Tumor of Borderline Malignancy;   Driving Mutations;   Progression-free Survival Intervention:   Sponsor:   Lei Li Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among Colorectal Cancer Patients
Condition:   Colorectal Cancer Interventions:   Drug: Probiotic Formula Capsule;   Drug: Placebos Sponsors:   University of Jordan;   King Hussein Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Conditions:   Stage III Non-small-cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Radiotherapy Side Effect Intervention:   Radiation: Heterogeneously Hypofractionated Radiotherapy Sponsors:   Danish Lung Cancer Group;   Odense University Hospital;   Rigshospitalet, Denmark;   Vejle Hospital;   Herlev Hospital;   Aarhus University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

Efficacy Study of CPC634 (CriPec ® Docetaxel) in Platinum Resistant Ovarian Cancer
Conditions:   Cancer;   Ovarian Cancer Intervention:   Drug: CPC634 (CriPec® docetaxel) Sponsor:   Cristal Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Condition:   Relapsed or Refractory Chronic Lymphocytic Leukemia Interventions:   Drug: CYC065;   Drug: Venetoclax Sponsors:   Cyclacel Pharmaceuticals, Inc.;   M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2018 Category: Research Source Type: clinical trials

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Conditions:   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   CD22 Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia Interventions:   Biological: Blinatumomab;   Biological: Inotuzumab Ozogamicin Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2018 Category: Research Source Type: clinical trials